Efficient Workflow. Top Accuracy. Better Outcomes.
Major Hospitals
AI Accuracy
Global Standard
Established
Expanding beyond acute triage into prognostic intelligence
predicting outcomes using imaging and patient metadata.
The PurpleAI Story
Our Identity & Mission
PurpleAI is a fast-growing medical AI innovator transforming stroke care through intelligent automation and predictive insight. Founded as an independent company in October 2024 (after operating within SK Group since 2019), PurpleAI is dedicated to enhancing workflow efficiency, diagnostic accuracy, and patient outcomes.
Our Future Vision
PurpleAI is now expanding its Hyper Insight™ portfolio across multiple imaging modalities and advancing into multimodal, data-driven predictive analytics. Its upcoming flagship, StrokeShieldAI, is built to anticipate and monitor high-risk complications after initial stroke treatment—providing clinicians with real-time foresight for earlier intervention and better outcomes.
Our Journey
Milestones in AI-Powered Healthcare Innovation
R&D Start
- Established SK C&C Digital Healthcare Team
- Initiated R&D based on partnerships with medical institutions (Seoul National University Hospital, Ajou University Hospital)
Obtained Regulatory Approvals from MFDS (Korea FDA)
- Acquired Medical Device Manufacturing License
- Obtained GMP Certification
- Acquired Class III Medical Device Product Approvals
Market Entry & Competitive Validation
- Secured over 10% market share in general hospitals in Korea
- Designated as breakthrough medical device by the Ministry of Food & Drug Safety (MFDS)
- Received U.S. FDA clearance
Establishment of PurpleAI for R&D: Predictive Stroke Care
- Approved for venture spin-off and established PurpleAI Inc.
- Acquired SK C&C's medical AI business
- Raised Pre-A Round investment (totaling 2.5 billion KRW)
Leading the Future of AI Healthcare
PurpleAI continues to push the boundaries of AI-powered stroke care, delivering innovative solutions that save lives and empower medical professionals worldwide.